GNE肌病 - 流行病學考察:2030年

本報告提供GNE肌病調查分析，過去、未來的流行病學，以美國、歐洲5個國家 (德國，西班牙，義大利，法國，英國) 、日本的市場趨勢為焦點，提供治療流程、治療指南，流行病學方案相關的系統性資訊。

目錄

第1章 主要考察

第2章 GNE肌病的摘要整理

第3章 GNE肌病:疾病的背景和概要

• 簡介
• 徵兆與症狀
• 病理生理學
• 危險因素
• 診斷

第4章 病人歷程

第5章 流行病學和患者族群

• 流行病學的主要調查結果
• 前提條件與根據:主要7個國家
• 流行病學方案:主要7個國家
• 美國的流行病學
• 歐洲5個國家的各國流行病學
• 日本的流行病學

第6章 治療流程，目前治療，醫療行為

• GNE肌病的治療和管理
• GNE肌病的治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

DelveInsight's 'GNE Myopathy - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted GNE Myopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017-2030

GNE Myopathy Understanding

The DelveInsight GNE Myopathy epidemiology report gives a thorough understanding of the GNE Myopathy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for GNE Myopathy in the US, Europe, and Japan. The report covers the detailed information of the GNE Myopathy epidemiology scenario in seven major countries (US, EU5, and Japan).

GNE Myopathy Epidemiology Perspective by DelveInsight

The GNE Myopathy epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The GNE Myopathy epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The GNE Myopathy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

GNE Myopathy Detailed Epidemiology Segmentation

The GNE Myopathy epidemiology covered in the report provides historical as well as forecasted GNE Myopathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight GNE Myopathy report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

• The GNE Myopathy report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The GNE Myopathy Epidemiology Report and Model provide an overview of the risk factors and global trends of GNE Myopathy in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of GNE Myopathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of GNE Myopathy
• The report provides the segmentation of the GNE Myopathy epidemiology

Report Highlights:

• 11-Year Forecast of GNE Myopathy epidemiology
• 7MM Coverage
• Total Cases of GNE Myopathy
• Total Cases of GNE Myopathy according to segmentation
• Diagnosed cases of GNE Myopathy

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to GNE Myopathy ?
• What are the key findings pertaining to the GNE Myopathy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of GNE Myopathy across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
• What is the disease risk, burden and unmet needs of the GNE Myopathy ?
• What are the currently available treatments of GNE Myopathy ?

Reasons to buy:

• The GNE Myopathy Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global GNE Myopathy market
• Quantify patient populations in the global GNE Myopathy market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GNE Myopathy therapeutics in each of the markets covered
• Understand the magnitude of GNE Myopathy population by its epidemiology
• The GNE Myopathy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of GNE Myopathy

3. GNE Myopathy : Disease Background and Overview

• 3.1. Introduction
• 3.2. Sign and Symptoms
• 3.3. Pathophysiology
• 3.4. Risk Factors
• 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

• 5.1. Epidemiology Key Findings
• 5.2. Assumptions and Rationale: 7MM
• 5.3. Epidemiology Scenario: 7MM
  • 5.3.1. GNE Myopathy Epidemiology Scenario in the 7MM (2017- 2030)
• 5.4. United States Epidemiology
  • 5.4.1. GNE Myopathy Epidemiology Scenario in the United States (2017- 2030)
• 5.5. EU-5 Country-wise Epidemiology
  • 5.5.1. Germany Epidemiology
    • 5.5.1.1. GNE Myopathy Epidemiology Scenario in Germany (2017- 2030)
  • 5.5.2. France Epidemiology
    • 5.5.2.1. GNE Myopathy Epidemiology Scenario in France (2017- 2030)
  • 5.5.3. Italy Epidemiology
    • 5.5.3.1. GNE Myopathy Epidemiology Scenario in Italy (2017- 2030)
  • 5.5.4. Spain Epidemiology
    • 5.5.4.1. GNE Myopathy Epidemiology Scenario in Spain (2017- 2030)
  • 5.5.5. United Kingdom Epidemiology
    • 5.5.5.1. GNE Myopathy Epidemiology Scenario in the United Kingdom (2017-2030)
• 5.6. Japan Epidemiology
  • 5.6.1. GNE Myopathy Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

• 6.1. GNE Myopathy Treatment and Management
• 6.2. GNE Myopathy Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

• 9.1. Bibliography
• 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

• Table 1: GNE Myopathy Epidemiology in 7MM (2017-2030)
• Table 2: GNE Myopathy Diagnosed and Treatable Cases in 7MM (2017-2030)
• Table 3: GNE Myopathy Epidemiology in the United States (2017-2030)
• Table 4: GNE Myopathy Diagnosed and Treatable Cases in the United States (2017-2030)
• Table 5: GNE Myopathy Epidemiology in Germany (2017-2030)
• Table 6: GNE Myopathy Diagnosed and Treatable Cases in Germany (2017-2030)
• Table 7: GNE Myopathy Epidemiology in France (2017-2030)
• Table 8: GNE Myopathy Diagnosed and Treatable Cases in France (2017-2030)
• Table 9: GNE Myopathy Epidemiology in Italy (2017-2030)
• Table 10: GNE Myopathy Diagnosed and Treatable Cases in Italy (2017-2030)
• Table 11: GNE Myopathy Epidemiology in Spain (2017-2030)
• Table 12: GNE Myopathy Diagnosed and Treatable Cases in Spain (2017-2030)
• Table 13: GNE Myopathy Epidemiology in the United Kingdom (2017-2030)
• Table 14: GNE Myopathy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
• Table 15: GNE Myopathy Epidemiology in Japan (2017-2030)
• Table 16: GNE Myopathy Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

• Figure 1: GNE Myopathy Epidemiology in 7MM (2017-2030)
• Figure 2: GNE Myopathy Diagnosed and Treatable Cases in 7MM (2017-2030)
• Figure 3: GNE Myopathy Epidemiology in the United States (2017-2030)
• Figure 4: GNE Myopathy Diagnosed and Treatable Cases in the United States (2017-2030)
• Figure 5: GNE Myopathy Epidemiology in Germany (2017-2030)
• Figure 6: GNE Myopathy Diagnosed and Treatable Cases in Germany (2017-2030)
• Figure 7: GNE Myopathy Epidemiology in France (2017-2030)
• Figure 8: GNE Myopathy Diagnosed and Treatable Cases in France (2017-2030)
• Figure 9: GNE Myopathy Epidemiology in Italy (2017-2030)
• Figure 10: GNE Myopathy Diagnosed and Treatable Cases in Italy (2017-2030)
• Figure 11: GNE Myopathy Epidemiology in Spain (2017-2030)
• Figure 12: GNE Myopathy Diagnosed and Treatable Cases in Spain (2017-2030)
• Figure 13: GNE Myopathy Epidemiology in the United Kingdom (2017-2030)
• Figure 14: GNE Myopathy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
• Figure 15: GNE Myopathy Epidemiology in Japan (2017-2030)
• Figure 16: GNE Myopathy Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report